GBM
61 programs · 55 companies
Programs
61
Companies
55
Trials
53
MOAs
39
MALT1iTYK2iMeniniCD3xCD20BTKiSGLT2iWEE1iIL-13iTNFiAuroraAi
Drugs
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-2735 | Phase 2/3 | Cl18.2 | ||
| Nidasacituzumab | Approved | CFTR | ||
| Ivorelsin | Approved | JAK1 | ||
| Lisonaritide | Phase 3 | IL-13 | ||
| NVO-1361 | Phase 3 | CD38 | ||
| TAK-2403 | Phase 2 | WEE1 | ||
| BAY-3308 | Phase 1 | ALK | ||
| Doxafotisoran | Phase 1 | Cl18.2 | ||
| AMG-1919 | Phase 2/3 | CDK2 | ||
| Ribozanubrutinib | Approved | GPRC5D | ||
| Semasacituzumab | Phase 2 | AHR | ||
| 207-2754 | Phase 1/2 | KRASG12D | ||
| Tirasotorasib | Phase 1 | CFTR | ||
| AKR-4818 | Approved | CD20 | ||
| APG-2066 | Phase 2 | TNFα | ||
| SLR-5251 | Phase 3 | KRASG12D | ||
| CSL-4459 | NDA/BLA | KRASG12D | ||
| Mavurasimod | Phase 2 | PCSK9 | ||
| SEO-IIT-994 | Phase 2 | JAK2 | ||
| Niraratamab | Phase 2 | B7-H3 | ||
| CGE-1556 | Phase 1 | KRASG12C | ||
| Datofutibatinib | Approved | GLP-1R | ||
| Pexasertib | Preclinical | CD38 | ||
| Mavuinavolisib | Preclinical | VEGF | ||
| Datorasimod | Approved | C5 | ||
| Pemibrutinib | Approved | TIM-3 | ||
| PRT-4395 | Phase 2 | GPRC5D | ||
| Nidatuximab | Preclinical | MALT1 | ||
| Voxafotisoran | Phase 3 | JAK1 | ||
| 086-8509 | Phase 2/3 | LAG-3 | ||
| Doxarelsin | Phase 1/2 | PD-1 | ||
| Zanutuximab | Phase 2 | TYK2 | ||
| QUA-2029 | Phase 1/2 | PRMT5 | ||
| TER-8481 | Phase 1/2 | KRASG12C | ||
| RYT-9424 | Phase 2/3 | CGRP | ||
| ORC-2834 | Phase 2/3 | LAG-3 | ||
| Motafutibatinib | Approved | KIF18A | ||
| TRV-1449 | Phase 2 | PI3Kα | ||
| PSI-4605 | Preclinical | BCL-2 | ||
| HYK-8507 | Phase 1 | GLP-1R | ||
| 488-6595 | Approved | CDK4/6 | ||
| 003-4903 | Phase 3 | BCMA | ||
| TOR-2175 | Preclinical | SGLT2 | ||
| Nidacilimab | Approved | JAK2 | ||
| Pemizasiran | NDA/BLA | GLP-1R | ||
| IMV-2493 | Phase 2 | PSMA | ||
| Datocapivasertib | Phase 1/2 | B7-H3 | ||
| MRK-9679 | NDA/BLA | Menin | ||
| MRK-474 | Phase 3 | PCSK9 | ||
| MRK-3890 | Phase 2 | FXIa | ||
| 654-1692 | Phase 2 | DLL3 | ||
| BAY-8160 | Phase 1/2 | KIF18A | ||
| Miriratamab | Phase 2/3 | GPRC5D | ||
| GRA-2645 | Phase 2 | FLT3 | ||
| Elracilimab | NDA/BLA | IL-17A | ||
| TAB-303 | Phase 3 | SHP2 | ||
| NAT-IIT-452 | Phase 3 | FXIa | ||
| NAT-IIT-330 | Phase 2 | HER2 | ||
| Zoricapivasertib | Phase 1 | WRN | ||
| Doxasacituzumab | Phase 1 | SGLT2 | ||
| Sovarelsin | Phase 1/2 | CD123 |
Trials (53)
| NCT | Drug | Phase | Status |
|---|---|---|---|
| NCT08786407 | JNJ-2735 | Phase 2/3 | Completed |
| NCT04621678 | JNJ-2735 | Phase 2/3 | Not yet recr... |
| NCT05752937 | Nidasacituzumab | Approved | Not yet recr... |
| NCT06221742 | Nidasacituzumab | Approved | Recruiting |
| NCT07116795 | Ivorelsin | Approved | Terminated |
| NCT04511223 | Lisonaritide | Phase 3 | Not yet recr... |
| NCT07194718 | Lisonaritide | Phase 3 | Active |
| NCT04089133 | TAK-2403 | Phase 2 | Terminated |
| NCT08609370 | BAY-3308 | Phase 1 | Recruiting |
| NCT08987105 | AMG-1919 | Phase 2/3 | Not yet recr... |
| NCT03660032 | AMG-1919 | Phase 2/3 | Not yet recr... |
| NCT03632014 | Ribozanubrutinib | Approved | Terminated |
| NCT08562823 | Semasacituzumab | Phase 2 | Completed |
| NCT08030625 | 207-2754 | Phase 1/2 | Completed |
| NCT03792158 | Tirasotorasib | Phase 1 | Completed |
| NCT04789551 | AKR-4818 | Approved | Completed |
| NCT06876875 | AKR-4818 | Approved | Recruiting |
| NCT04823620 | APG-2066 | Phase 2 | Active |
| NCT06360274 | SLR-5251 | Phase 3 | Recruiting |
| NCT03605023 | SLR-5251 | Phase 3 | Not yet recr... |